Antibiotic resistance is the third leading cause of death, globally, claiming almost 5 million lives every year, with this projected to increase …
Inceptua Early Access is proud to sponsor this year’s Biocom Global Partnering Conference. Dive into expert insights on early access pathways, global distribution models, and real‑world program design. Get in contact, and set up an intro call to learn more about how we can support your business
When patients have a life threatening or debilitating illness, their physicians have exhausted current treatment options or there simply aren’t any treatment options available or they are unable to enter a clinical trial, mechanisms exist across the globe to enable access to (pre-approval access, managed access , compassionate use , expanded access ) to medicines where they are not approved in the country of intended use.
Healthcare professionals often seek to access these medicines for their patients, and biopharmaceutical companies developing innovative medicines are increasingly making these medicines available to patients through early access programs.
Patient Forecasting in Early Access Programs
When planning an early access program, a key consideration is ‘how many patients might participate?’
Practical Perspectives on Real-World Evidence in Early Access
Bridging the Gap between Hype and Reality
Antibiotic resistance is the third leading cause of death, globally, claiming almost 5 million lives every year, with this projected to increase …
Antibiotic resistance is the third leading cause of death, globally, claiming almost 5 million lives every year, with this projected to increase …
